This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Do Options Traders Know Something About Alcon (ALC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Alcon (ALC) stock based on the movements in the options market lately.
Here's Why Alcon (ALC) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alcon (ALC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
by Zacks Equity Research
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Countdown to Alcon (ALC) Q2 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Philips (PHG) Extends Isala Partnership, Boosts Customer Base
by Zacks Equity Research
Philips (PHG) extends its partnership Isala hospital to optimize the latter's healthcare processes, expanding its customer base.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
Here's Why Alcon (ALC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
by Zacks Equity Research
DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
by Nalak Das
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and Alcon (ALC) have performed compared to their sector so far this year.
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
by Zacks Equity Research
Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.